KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm. 2026;40(1):41-46 / www.klinickafarmakologie.cz 46 PŘEHLEDOVÉ ČLÁNKY Léčiva ze skupiny ARTA a jejich interakce s perorálními antikoagulancii LITERATURA 1. Koudelková, M et al. Prostascreening.cz – Program časného záchytu karcinomu prostaty [online]. Praha: Ústav zdravotnických informací a statistiky ČR, 2024. [cit. 2025-08-22]. Available from: https://www.prostascreening.cz. Verze 1.0 2. Ikushima S, Ono R, Fukuda K, et al. Trousseau’s syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2016;46(3):204-208. 3. Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11. 4. Leblanc K, Edwards SJ, Dranitsaris G, et al. Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus. Cancers (Basel). 2024;16(19):3336. 5. Dai C, Dehm SM, Sharifi N. Targeting the Androgen Signaling Axis in Prostate Cancer. J Clin Oncol. 2023;41(26):4267-4278. 6. Gregorová J, Tašková I. Antikoagulační terapie. Praha: Maxdorf; 2022. 7. American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024. 8. Chen Y, Zhou Q, Hankey W, et al. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis. 2022;13(7):632. 9. Soumarová R. Onkologie. Praha: Univerzita Karlova, nakladatelství Karolinum; 2025. 10. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-790. 11. Souhrn údajů o přípravku (SPC) – Xtandi; 2025 12. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494-503. 13. de Vries R, Jacobs F, Mannens G, et al. Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes. Drug Metab Dispos. 2019;47(5):453-464. 14. Duran I, Carles J, Bulat I, et al. Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer. Clin Pharmacokinet. 2020;59(9):1135-1148. 15. Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007. 16. Zurth C, Koskinen M, Fricke R, et al. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. Eur J Drug Metab Pharmacokinet. 2019;44(6):747-759. 17. Shore N, Zurth Ch, Fricke R, et al. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Target Oncol. 2019;14(5):527-539. 18. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28(9):1496-501. 19. Han CS, Patel R, Kim IY. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Expert Opin Drug Metab Toxicol. 2015;11(6):967-975. 20. Montgomery RB, Vessella R, Mostaghel E, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-4454. 21. Ando T, Nishiyama T, Takizawa I, et al. Dihydrotestosterone synthesis pathways from inactive androgen 5α-androstane- -3β,17β-diol in prostate cancer cells: Inhibition of intratumoural 3β-hydroxysteroid dehydrogenase activities by abiraterone. Sci Rep. 2016;6:32198. 22. Li R, Evaul K, Sharma KK, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012;18(13):3571-3579. 23. Acharya M, Bernard A, Gonzalez M, et al. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol. 2012;69(6):1583-1590. 24. Souhrn údajů o přípravku (SPC) – Zytiga; 2025. 25. Büchler T. Klinická onkologie. Praha: Maxdorf; 2023. 26. Ferri N, Colombo E, Tenconi M, et al. Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. Pharmaceutics. 2022;14(6):1120. 27. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. 28. Arachchillage DJ, Platton S, Hickey K, et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2024;205(3):855-880. 29. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153. 30. Meyer G. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729-1735. 31. Lee YJ, Park J-K, Uhm J-S, et al. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol. 2016;203:372-378. 32. Giustozzi M, Agnelli G, Del Toro-Cervera J, et al. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. Thromb Haemost. 2020;120(7):1128-1136. 33. Sabatino J, De Rosa S, Polimeni A, et al. Direct Oral Anticoagulants in Patients With Active Cancer: A Systematic Review and Meta-Analysis. JACC CardioOncol. 2020;2(3):428-440. 34. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018;378(7):615-624. 35. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382(17):1599-1607. 36. Górnicki T, Bułdyś K, Zielińska D, et al. Direct-Acting Oral Anticoagulant Therapy in Cancer Patients-A Review. Cancers (Basel). 2023;15(10):2697. 37. Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. Blood. 2019;133(4):291-298. 38. Hindley B, Lip GYH, McCloskey AP, et al. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. Expert Opin Drug Metab Toxicol. 2023;19(12):911-923. 39. Souhrn údajů o přípravku (SPC) – Pradaxa; 2025 40. Byon W, Garonzik S, Boyd RA, et al. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265-1279. 41. Souhrn údajů o přípravku (SPC) – Eliquis; 2025. 42. Kvasnička T, Malikova I, Zenahlikova Z, et al. Rivaroxaban – Metabolism, Pharmacologic Properties and Drug Interactions. Curr Drug Metab. 2017;18(7):636-642. 43. Souhrn údajů o přípravku (SPC) – Xarelto; 2025. 44. Souhrn údajů o přípravku (SPC) – Lixiana; 2025. 45. Mar PL, Gopinathannair R, Gengler BE, et al. Drug Interactions Affecting Oral Anticoagulant Use. Circ Arrhythm Electrophysiol. 2022;15(6):e007956. 46. Souhrn údajů o přípravku (SPC) – Warfarin Orion; 2025. 47. Shatzel JJ, Daughety MM, Olson SR, et al. Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide. J Oncol Pract. 2017;13(11):720-727. 48. Otsuka Y, Poondru S, Bonate PL, et al. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. J Pharmacokinet Pharmacodyn. 2023;50(5):365-376. 49. Lennep BW, Mack J, Poondru S, et al. Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy. Drug Saf. 2024;47(7):617-641. 50. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. 51. Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clin Pharmacokinet. 2015;54(10):1057-1069. 52. Parrett JL, Reaves AB, Self TH, et al. Enzalutamide-warfarin interaction necessitating warfarin dosage adjustment: A case report of successful clinical management. J Clin Pharm Ther. 2018;43(2):276-279. 53. Casserly EA, Rogers SE, Keisner SV. Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient. J Oncol Pharm Pract. 2017;23(1):68-70. 54. Potdar R, Gartrell BA, Given R, et al. Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies. Am J Cancer Res. 2022;12(1):445-450. 55. Souhrn údajů o přípravku (SPC) – Erleada; 2025. 56. Podgoršek E, Mehra N, van Oort IM, et al. Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide. Clin Pharmacokinet. 2023;62(8):1049-1061. 57. Boujonnier F, Lemaitre F, Scailteux LM. Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information. Cardiovasc Drugs Ther. 2024;38(4):757-767. 58. Souhrn údajů o přípravku (SPC) – Nubeqa; 2025. 59. Benoist GE, Hendriks RJ, Mulders PFA, et al. Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. Clin Pharmacokinet. 2016;55(11):1369-1380. 60. Monbaliu J, Gonzalez M, Bernard A, et al. In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. Drug Metab Dispos. 2016;44(10):1682-1691. 61. Dubinsky S, Thawer A, McLeod AG, et al. Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone. Support Care Cancer. 2019;27(9):3209-3217. 62. Mithoowani S, Tan CW, Siegal DM. Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions. Int J Lab Hematol. 2025 Apr 22.
RkJQdWJsaXNoZXIy NDA4Mjc=